Clinical Trial Update: Race Impact on Efficacy of Niraparib Plus Abiraterone Acetate and Prednisone in Patients With Homologous Repair Deficient Castration-resistant Prostate Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial assessing race-related differences in the efficacy of niraparib plus abiraterone acetate and prednisone in homologous recombination deficiency-ass…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer
• Prostate Cancer

Drugs mentioned

• PREDNISONE (Prednisone)
• Zejula (Niraparib)
• Zytiga (abiraterone acetate)

Snippet

Sponsor: Latin American Cooperative Oncology Group | Conditions: Prostate Cancer, Castrate Resistant Prostate Cancer | Phase 2 | Status: WITHDRAWN